Barrett JS et al
The Medicare GLP-1 Bridge is a nationwide demonstration program that will be separate from Part D coverage, meaning Part D sponsors will not have to opt into the demonstration for eligible beneficiaries to gain access, nor will Part D sponsors bear any financial risk for costs incurred by their enrollees associated with the demonstration
The benefits of GLP-1s dont come without side effects
Mortensen KN, Gjedde A, Thompson GJ, Herman P, Parent MJ, Rothman DL, et al
Parallel efforts are exploring new indications, including neurodegenerative and substance use disorders, metabolic liver disease, arthritis, type 1 diabetes and inflammatory bowel disease
The MHRA has not approved any GLP-1 receptor agonist for use below the labelled doses, and this approach falls outside current prescribing guidelines